Company
Tandem
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
25
510(k), De Novo and PMA
Device trials
18
As lead sponsor, any status
Adverse event reports
240,850
Received Nov 1, 2025 to Nov 20, 2026
Recall records
15
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Tandem, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Tandem.
Latest FDA decisions
The 8 newest of 25 since 2015.
- Control-IQ+ technology510(k)
K260429 · Decided Apr 24, 2026 · 73 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
K253074 · Decided Nov 6, 2025 · 44 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K250792 · Decided Sep 24, 2025 · 194 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
22 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceRecruiting
NCT07211126 · 350 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 2027
Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) · For: Diabetes Mellitus, Type 1
Sites: Agen, France; Angers, France; Bron, France · 25 sites in all
NCT06717451 · 144 participants · Start Jan 30, 2025 · Primary completion Aug 10, 2026
Device: Control-IQ Technology v1.5 · For: Type 1 Diabetes
Sites: San Diego, California
NCT07325461 · 20 participants · Start Feb 18, 2026 · Primary completion Jun 24, 2026
Device: SteadiSet Infusion Set · For: Diabetes Mellitus, Type 1
Sites: Stanford, California
15 more trials with a free account
Reports received
240,850
Received Nov 1, 2025 to Nov 20, 2026. Includes 3 of another or unstated type.
Malfunction reports
214,469
89% of reports
Injury reports
26,338
11% of reports
Death reports
40
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 14,074 | 1,347 | 0 | 0 |
| Jan 24 | 14,795 | 1,536 | 1 | 0 |
| Feb 24 | 13,092 | 1,521 | 1 | 1 |
| Mar 24 | 17,493 | 1,796 | 1 | 0 |
| Apr 24 | 17,984 | 2,141 | 6 | 0 |
| May 24 | 17,654 | 2,184 | 1 | 0 |
| Jun 24 | 15,015 | 1,828 | 0 | 0 |
| Jul 24 | 22,880 | 2,686 | 2 | 0 |
| Aug 24 | 22,619 | 2,518 | 4 | 0 |
| Sep 24 | 18,332 | 1,874 | 4 | 0 |
| Oct 24 | 19,767 | 2,242 | 7 | 0 |
| Nov 24 | 15,115 | 1,660 | 2 | 0 |
| Dec 24 | 18,708 | 2,046 | 1 | 0 |
| Jan 25 | 22,351 | 2,061 | 2 | 0 |
| Feb 25 | 14,937 | 1,591 | 3 | 0 |
| Mar 25 | 16,982 | 1,879 | 3 | 0 |
| Apr 25 | 18,189 | 2,058 | 3 | 0 |
| May 25 | 17,517 | 2,280 | 4 | 0 |
| Jun 25 | 14,625 | 2,378 | 2 | 0 |
| Jul 25 | 24,336 | 3,274 | 3 | 0 |
| Aug 25 | 20,114 | 2,631 | 5 | 0 |
| Sep 25 | 19,226 | 2,860 | 0 | 0 |
| Oct 25 | 19,550 | 2,718 | 2 | 0 |
| Nov 25 | 16,398 | 2,142 | 2 | 0 |
| Dec 25 | 21,045 | 2,387 | 5 | 1 |
| Jan 26 | 17,617 | 2,125 | 5 | 0 |
| Feb 26 | 16,991 | 1,921 | 2 | 0 |
| Mar 26 | 18,423 | 2,336 | 1 | 0 |
| Apr 26 | 18,106 | 2,592 | 6 | 0 |
| May 26 | 16,565 | 2,096 | 1 | 0 |
| Jun 26 | 17,731 | 2,298 | 4 | 0 |
| Jul 26 | 18,816 | 2,038 | 1 | 1 |
| Aug 26 | 17,464 | 2,152 | 6 | 1 |
| Sep 26 | 17,697 | 2,139 | 5 | 0 |
| Oct 26 | 17,616 | 2,112 | 2 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
3 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0316-2027 · Started Sep 23, 2026 · Posted by FDA Oct 30, 2026
Reason given: Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain...
Cause as FDA categorized it: Process change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Z-3330-2026 · Started Jul 16, 2026 · Posted by FDA Sep 29, 2026
Reason given: A beta (early-release) version of the iOS application, version 2.13 (TestFlight) had a software issue preventing successful pairing of the t:slim application with Abbott FreeStyle Libre 3 Plus (FSL3P) continuous glucose monitoring (CGM) sensors, resulting in the insulin pump being unable to establish a near-field...
Cause as FDA categorized it: Software Design Change · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Z-1636-2026 · Started Jan 30, 2026 · Posted by FDA Mar 25, 2026
Reason given: The Czech language user guide contained multiple translation errors. The most significant error was that it incorrectly instructs users to verify that the infusion set is connected to the body, when it should instead direct users to confirm that the infusion set is not connected to the body. Following this instruction...
Cause as FDA categorized it: Process change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
12 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.